Anemia in cancer: Some pathophysiological aspects

Oncologist

Volumn 8, Issue SUPPL. 1, 2003, Pages 19-21

  Dicato, Mario ^a  

^a Haematology Oncology   (Luxembourg)

Author keywords

Erythropoietin; Neoplasms; Quality of life; TNF alpha

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANEMIA; BONE MARROW DISEASE; BONE MARROW TOXICITY; CANCER PATIENT; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG INDUCED DISEASE; GASTROINTESTINAL DISEASE; HEMOGLOBINOPATHY; HEMOLYSIS; HUMAN; HYPERSPLENISM; INTESTINE RESECTION; MALNUTRITION; NEPHROTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION INJURY; THALASSEMIA;

EID: 0037224609     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.8-suppl_1-19     Document Type: Conference Paper

References (10)

1. Mercadante S, Gebbia V, Marrazzo A et al. Anemia in cancer: pathophysiology and treatment. Cancer Treat Rev 2000;26:303-311.
2. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001;412:641-647.
3. Yu X, Lin CS, Costantini F et al. The human erythropoietin receptor gene rescues erythropoiesis and developmental defects in the erythropoietin receptor null mouse. Blood 2001;98:475-477.
4. Papadaki HA, Kritikos HD, Valatas V et al. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 2002;100:474-482.
5. Curt GA, Breitbart W, Cella D et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. The Oncologist 2000;5:353-360.
6. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
7. Glaspy J, Degos L, Dicato M et al. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. The Oncologist 2002;7:126-135.
8. Adamson JW, Ludwig H. Predicting the hematopoietic response to recombinant human erythropoietin (Epoietin alfa) in the treatment of the anemia of cancer. Oncology 1999;56:46-53.
9. Wu WC, Rathore SS, Wang Y et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001;345:1230-1236.
10. Lavey RS. Clinical trial experience using erythropoietin during radiation therapy. In: Vaupel P, Kelleher D, eds. Tumor Hypoxia. Stuttgart, Germany: WVG Publishers, 1999:99-105.